ALGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, Aligos Therapeutics Inc (ALGS) does not present a compelling buy opportunity for a beginner investor with a long-term investment strategy. While there are positive catalysts such as the licensing agreement and FDA Fast Track Designation, the company's financial performance is weak, and there are no strong trading signals or clear upward momentum in technical indicators. The stock is better suited for monitoring rather than immediate investment.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 44.728, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 7.378) but below the pivot point (8.062), suggesting limited upside potential in the short term.
Licensing agreement with Xiamen Amoytop, securing $25 million upfront and potential milestone payments of up to $420 million.
FDA Fast Track Designation for pevifoscorvir sodium, expediting clinical development.
Positive interim results from Phase 2 study of pevifoscorvir sodium, showing good tolerability and no safety signals.
Weak financial performance in Q4 2025, with revenue, net income, and EPS showing significant YoY declines.
Analysts have reduced price targets (e.g., Jefferies lowered from $60 to $48).
Stock trend analysis suggests a high probability of minor declines in the short term.
The company's Q4 2025 financials show significant declines: Revenue dropped by -73.13% YoY to $169,000, Net Income fell by -75.80% YoY to -$19.88 million, and EPS decreased by -85.40% YoY to -1.91. Gross Margin remained at 100%, but overall financial health is weak.
Analysts have a Buy rating with a price target of $48. However, Jefferies recently reduced its target from $60, citing asymmetric risk/reward and the potential for differentiation in the hepatitis B treatment market. Expectations have been reset following prior class failures.
